The Weekly Roundup: October 27-31

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Withdrawing Your Assets in Retirement: 2 Important Factors to Consider

Dermatologists can navigate retirement planning by addressing inflation and tax strategies, ensuring sustainable wealth distribution for a secure financial future.

New 52-Week Data Reinforce Deucravacitinib’s Benefits for Psoriatic Arthritis and SLE

Bristol Myers Squibb reveals promising data on deucravacitinib's efficacy for psoriatic arthritis and systemic lupus erythematosus, highlighting its potential as a new treatment option.

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, Unveil the Vision for the Inaugural NDLS

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

ICYMI: Quoin's QRX003 Receives FDA Orphan Drug Status for Netherton Syndrome

Quoin Pharmaceuticals' QRX003 granted FDA Orphan Drug Designation, advancing treatment for Netherton Syndrome, a rare dermatological disease.

ENCOMPASS Study Reveals Major Unmet Needs and the Rise of Oral Treatments in Psoriasis

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

A Long Line of Strong Women

Explore a personal journey of resilience and proactive choices in the fight against breast cancer during Breast Cancer Awareness Month.

Bimekizumab Demonstrates Sustained Reduction in Flares in Moderate to Severe HS Over 2 Years

According to a poster at Fall Clinical 2025, over 80% of patients remained flare-free across the 2-year period.

Cosmetic Trends of Dermatologic Interest in 2025

Explore the latest cosmetic trends for 2025, including artificial freckles, antiaging sunscreens, and IV NAD+ infusions, as discussed by Zoe Diana Draelos, MD.

Ruxolitinib Cream Shows Strong AD Efficacy and Rapid Itch Relief in TRuE-AD4 Trial

Incyte reveals promising TRuE-AD4 trial results for ruxolitinib cream, showcasing its effectiveness and safety for adults with moderate atopic dermatitis.

6th Inflammatory Skin Disease Summit: The Translational Revolution

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.

Rheumatologic Dermatology and Breast Cancer: What Every Dermatologist Should Know

Explore the intricate relationship between rheumatologic dermatology and breast cancer, highlighting diagnostic challenges and treatment insights for dermatologists.

Building NP and PA Unity Through Education, Leadership, and Collaboration

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

Fall Clinical 2025: Complete Conference Recap

Catch up on coverage from the entire 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

Derm Dispatch: A Lifelong Journey with Eczema and the Power of Compassionate Care

Chava Wald shares her inspiring journey with AD, advocating for patient empowerment and compassionate care during Eczema Awareness Month.

Indomo Launches Investigational At-Home Injectable Candidate to Revolutionize Acne Treatment

Indomo's ClearPen could revolutionize acne treatment with at-home microneedle injections, offering instant access to effective corticosteroid therapy for inflammatory lesions.

Lisa Swanson, MD, On Emerging Pediatric Psoriasis Therapies

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.

Upadacitinib Achieves Positive Phase 3 Results in Non-Segmental Vitiligo

In 2 replicate phase 3 trials, once-daily upadacitinib 15 mg significantly improved total and facial repigmentation in adults and adolescents with non-segmental vitiligo, with a safety profile consistent with prior indications.

Advancing the Management of Melasma and Hyperpigmentation in Skin of Color

At Fall Clinical 2025, Andrew Alexis, MD, reviewed topical, oral, and procedural interventions with patients with melasma and hyperpigmentation, especially in patients with skin of color.

Clinical Pearls from the PDPA Sixth Annual Keystone Dermatology Conference: Day 2

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Pennsylvania Dermatology Physician Assistants (PDPA) Keystone Dermatology Conference.

AVTX-009 Completes Enrollment in HS Phase 2 Trial

Avalo Therapeutics completes enrollment in the LOTUS trial for AVTX-009, targeting hidradenitis suppurativa with promising IL-1β inhibition.

What Living With Psoriasis Taught Me About Adherence—and Why Clinical Research Must Change

Stephanie Alvarez, marketing director of Cognivia, details her experience with psoriasis and why she believes clinical trials should reflect more real-world patients and scenarios.

Dermatology Times October 2025 Print Recap

Learn more about the in-depth topics covered in the October 2025 print issue of Dermatology Times.

An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

FDA Modernizes Biosimilar Approval to Cut Costs and Speed Access

Updated FDA policies eliminate many comparative efficacy trials, reducing biosimilar development time and cost by relying more on analytical testing.

Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

Lindsay Ackerman, MD, FAAD, Discusses Practical Tips for Ruxolitinib Application

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

Dermatology Times October 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of October.

What Dermatological Adverse Effects Can Patients With Breast Cancer Expect?

CURE spoke with experts about possible dermatologic adverse effects faced by patients with breast cancer.

New Guidelines Limit Long-Term Steroid Use in AD

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

The Next Frontier in CSU Therapy: Expert Insights on Barzolvolimab

Discover the latest advancements in CSU therapy, including Gil Yosipovitch's insights on barzolvolimab's promising results and its potential impact on patient care.

Top 5 Articles of the Month: October 2025

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Integrating Dermatology Into the Breast Cancer Care Team

Christopher Bunick, MD, PhD, emphasizes how dermatologists can improve outcomes through vigilant skin exams and collaborative care with oncology teams.

UCB's Bimekizumab Shows Sustained Efficacy Against HS Abscesses, Tunnels, and Pain Over 3 Years

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.

Celebrating Eczema Awareness Month 2025 with Dermatology Times

Discover the latest advancements in atopic dermatitis treatment and patient advocacy during Eczema Awareness Month, shaping future care and quality of life.